BidaskClub upgraded shares of MannKind (NASDAQ:MNKD) from a sell rating to a hold rating in a report published on Saturday, February 10th.
MNKD has been the topic of several other research reports. S&P Equity Research lowered their price target on MannKind from $3.49 to $2.77 in a research report on Thursday, January 25th. ValuEngine lowered MannKind from a sell rating to a strong sell rating in a research report on Tuesday, November 14th. Zacks Investment Research raised MannKind from a sell rating to a hold rating in a research report on Wednesday, January 10th. Maxim Group reaffirmed a hold rating on shares of MannKind in a research report on Tuesday, January 30th. Finally, HC Wainwright reaffirmed a buy rating on shares of MannKind in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. MannKind currently has an average rating of Hold and an average target price of $1.89.
MannKind (MNKD) opened at $2.84 on Friday. MannKind has a 1 year low of $0.67 and a 1 year high of $6.96. The company has a current ratio of 0.31, a quick ratio of 0.28 and a debt-to-equity ratio of -0.43.
Hedge funds and other institutional investors have recently modified their holdings of the company. Macquarie Group Ltd. bought a new position in shares of MannKind during the 3rd quarter worth approximately $156,000. Wells Fargo & Company MN boosted its stake in shares of MannKind by 51.5% during the 3rd quarter. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company’s stock worth $196,000 after acquiring an additional 30,589 shares during the period. Dupont Capital Management Corp bought a new position in shares of MannKind during the 3rd quarter worth approximately $219,000. Bank of New York Mellon Corp boosted its stake in shares of MannKind by 30.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 108,380 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 25,125 shares during the period. Finally, Dimensional Fund Advisors LP bought a new position in shares of MannKind during the 3rd quarter worth approximately $270,000. Institutional investors own 14.86% of the company’s stock.
WARNING: “MannKind (MNKD) Upgraded by BidaskClub to Hold” was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://weekherald.com/2018/02/21/mannkind-mnkd-raised-to-hold-at-bidaskclub.html.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.